Novartis Aims for Single Dose Malaria Cure with a Novel MoA, Long-Acting Aryl SF5 Compound
TNG462, a PRMT5 inhibitor by Tango Therapeutics, is in Ph. I/II trial for MTAP-deleted solid tumors, designed to bind with MTA in these tumors, causing synthetic lethality. A CNS-permeable analogue, TNG908, is also being tested for MTAP-deleted glioblastoma.
Reference News
Novartis Aims for Single Dose Malaria Cure with a Novel MoA, Long-Acting Aryl SF5 Compound
TNG462, a PRMT5 inhibitor by Tango Therapeutics, is in Ph. I/II trial for MTAP-deleted solid tumors, designed to bind with MTA in these tumors, causing synthetic lethality. A CNS-permeable analogue, TNG908, is also being tested for MTAP-deleted glioblastoma.